Fig. 7
Tumor growth inhibition in a colorectal cancer and lung cancer xenograft mouse model. (A) A xenograft model was established to test the cancer tissue growth inhibitory effect of rNDV and S519G mutant rNDV viruses. 1 × 107 cells/ml of HCT 116, HT-29, and A549 cells were inoculated into the left flank of the mouse. In each xenograft model, 12 SPF female BALB/c nude mice were randomly divided into groups with four mice per group (control, rNDV, and S519G mutant rNDV group). 107.0 TCID50/dose of rNDV and S519G mutant rNDV viruses and PBS were treated by intravenous injection. Virus inoculation was repeated three times at 2-day intervals. (B) The tumor volume was observed at 1–17 days-post virotherapy in HCT 116, HT-29, and A549 xenograft mouse models (n = 4, error bar: SEM, *p < 0.05, **p < 0.01, ***p < 0.001 compared with control group, #p < 0.05, ##p < 0.01, ###p < 0.001 compared with rNDV and S519G mutant rNDV group, and determined by the Student’s t-test). (C) Tumor size changes in mice were photographed after 0, 9, and 17 days-post virotherapy. (D) The tumor size of mice showed change (%) on the 17th days-post virotherapy based on the 1 day-post virotheray (n = 4, error bar: SEM, determined by the Student’s t-test). (E) Histology and immunohistochemistry of HCT116, HT-29, and A549 xenograft tumors. The representative images of immunohistochemistry for NDV HN are shown in brown. The rNDV; recombinant NDV